These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 26458165)

  • 21. Pathogenic T cell subsets in allergic and chronic inflammatory bowel disorders.
    Zundler S; Neurath MF
    Immunol Rev; 2017 Jul; 278(1):263-276. PubMed ID: 28658546
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New targets for mucosal healing and therapy in inflammatory bowel diseases.
    Neurath MF
    Mucosal Immunol; 2014 Jan; 7(1):6-19. PubMed ID: 24084775
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease.
    Bilal M; Nunes LV; Duarte MTS; Ferreira LFR; Soriano RN; Iqbal HMN
    Mar Drugs; 2021 Mar; 19(4):. PubMed ID: 33808253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treg subsets in inflammatory bowel disease and colorectal carcinoma: Characteristics, role, and therapeutic targets.
    van Herk EH; Te Velde AA
    J Gastroenterol Hepatol; 2016 Aug; 31(8):1393-404. PubMed ID: 26990130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gut-lung crosstalk in pulmonary involvement with inflammatory bowel diseases.
    Wang H; Liu JS; Peng SH; Deng XY; Zhu DM; Javidiparsijani S; Wang GR; Li DQ; Li LX; Wang YC; Luo JM
    World J Gastroenterol; 2013 Oct; 19(40):6794-804. PubMed ID: 24187454
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation.
    Pedersen J; LaCasse EC; Seidelin JB; Coskun M; Nielsen OH
    Trends Mol Med; 2014 Nov; 20(11):652-65. PubMed ID: 25282548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effector T Helper Cell Subsets in Inflammatory Bowel Diseases.
    Imam T; Park S; Kaplan MH; Olson MR
    Front Immunol; 2018; 9():1212. PubMed ID: 29910812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. T Lymphocyte Dynamics in Inflammatory Bowel Diseases: Role of the Microbiome.
    Larmonier CB; Shehab KW; Ghishan FK; Kiela PR
    Biomed Res Int; 2015; 2015():504638. PubMed ID: 26583115
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin A and inflammatory bowel diseases: from cellular studies and animal models to human disease.
    Barbalho SM; Goulart RA; Batista GLDSA
    Expert Rev Gastroenterol Hepatol; 2019 Jan; 13(1):25-35. PubMed ID: 30791845
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metabolome and inflammasome in inflammatory bowel disease.
    Nanau RM; Neuman MG
    Transl Res; 2012 Jul; 160(1):1-28. PubMed ID: 22687960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mathematical model of the roles of T cells in inflammatory bowel disease.
    Lo WC; Arsenescu RI; Friedman A
    Bull Math Biol; 2013 Sep; 75(9):1417-33. PubMed ID: 23760658
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic approaches in inflammatory bowel disease based on the immunopathogenesis.
    Siegmund B; Zeitz M
    Rocz Akad Med Bialymst; 2004; 49():22-30. PubMed ID: 15631310
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Focus on mechanisms of inflammation in inflammatory bowel disease sites of inhibition: current and future therapies.
    Van Assche G; Vermeire S; Rutgeerts P
    Gastroenterol Clin North Am; 2006 Dec; 35(4):743-56. PubMed ID: 17129811
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging therapeutic targets and strategies in Crohn's disease.
    Furfaro F; Fiorino G; Allocca M; Gilardi D; Danese S
    Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):735-44. PubMed ID: 26766496
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development.
    Waldner MJ; Neurath MF
    Semin Immunol; 2014 Feb; 26(1):75-9. PubMed ID: 24447345
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease.
    Di Sabatino A; Rovedatti L; Kaur R; Spencer JP; Brown JT; Morisset VD; Biancheri P; Leakey NA; Wilde JI; Scott L; Corazza GR; Lee K; Sengupta N; Knowles CH; Gunthorpe MJ; McLean PG; MacDonald TT; Kruidenier L
    J Immunol; 2009 Sep; 183(5):3454-62. PubMed ID: 19648266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of macrophages in inflammatory bowel diseases.
    Heinsbroek SE; Gordon S
    Expert Rev Mol Med; 2009 May; 11():e14. PubMed ID: 19439108
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel cytokine-targeted therapies and intestinal inflammation.
    Waldner MJ; Neurath MF
    Curr Opin Pharmacol; 2009 Dec; 9(6):702-7. PubMed ID: 19674937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. T-cell-directed therapies in inflammatory bowel diseases.
    Monteleone G; Caprioli F
    Clin Sci (Lond); 2010 Mar; 118(12):707-15. PubMed ID: 20350293
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of Autophagy in the Maintenance of Intestinal Homeostasis.
    Baxt LA; Xavier RJ
    Gastroenterology; 2015 Sep; 149(3):553-62. PubMed ID: 26170139
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.